WO2010125408A2 - Prostata-norm rectal suppositories for the treatment of prostatitis - Google Patents
Prostata-norm rectal suppositories for the treatment of prostatitis Download PDFInfo
- Publication number
- WO2010125408A2 WO2010125408A2 PCT/GE2010/000002 GE2010000002W WO2010125408A2 WO 2010125408 A2 WO2010125408 A2 WO 2010125408A2 GE 2010000002 W GE2010000002 W GE 2010000002W WO 2010125408 A2 WO2010125408 A2 WO 2010125408A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- prostatitis
- suppositories
- prostata
- norm
- Prior art date
Links
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 14
- 239000006215 rectal suppository Substances 0.000 title abstract description 6
- 239000000829 suppository Substances 0.000 claims abstract description 22
- 239000010677 tea tree oil Substances 0.000 claims abstract description 10
- 229940111630 tea tree oil Drugs 0.000 claims abstract description 10
- 108090000317 Chymotrypsin Proteins 0.000 claims abstract description 9
- 229960002376 chymotrypsin Drugs 0.000 claims abstract description 9
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims abstract description 9
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 12
- 230000009467 reduction Effects 0.000 abstract description 5
- 210000002307 prostate Anatomy 0.000 description 16
- 230000036407 pain Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 230000027939 micturition Effects 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 6
- 230000001568 sexual effect Effects 0.000 description 6
- 210000004907 gland Anatomy 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- 230000037007 arousal Effects 0.000 description 4
- 230000000721 bacterilogical effect Effects 0.000 description 4
- 230000003292 diminished effect Effects 0.000 description 4
- 238000007431 microscopic evaluation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000013507 chronic prostatitis Diseases 0.000 description 3
- 238000003759 clinical diagnosis Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000036299 sexual function Effects 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 206010036596 premature ejaculation Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- 241000722941 Achillea Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 101100505672 Podospora anserina grisea gene Proteins 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 108010009556 Vitaprost Proteins 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical class O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 108010020252 prostatilen Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Definitions
- the invention refers to medicine, in particular to urology and concerns rectal suppositories that are used for the treatment of prostatitis.
- the ratio of active ingredients in grams per one suppositoiy up to 2 g is as follows: Dipotassium glycyrrhizinate 0.025 - 0.1
- the unity of medicinal properties of said components makes it possible to create rectal suppositories of high therapeutic efficacy. It is characterized with a wide spectrum of biologic activities including anti-inflammatory, antibacterial, antiviral, immune modulating effects and is composed of organic, mostly natural substances, without known toxicity.
- the process of preparing of suppositories comprises the following steps: first the three components - dipotassium glycyrrhizinate, chymotrypsin in crystalline form and tea tree oil are mixed together. Then the diphyllic base Witepsol H- 15 is added to the resulted mixture and stirred until substance becomes homogenous. As a final step the homogenous mass is poured into the preformed patterns to obtain suppositories.
- composition in grams per one suppository up to 2 g.:
- composition in grams per one suppository up to 2 g.: Dipotassium glycyrrhizinate 0.05
- Chymotrypsin in crystalline form 0.015 Tea tree oil 0.025
- composition in grams per one suppository up to 2 g.:
- Tea tree oil 0.015 Witepsol H- 15 up to 2 Suppository has a yellowish color and has a smell characteristic of a tea tree oil, and it weighs about 1.5 -2 g. Suppositories can be kept for 2 years; they retain their biologic activity for this long if kept in cool place.
- the trade name of the suppository is "PROSTATA-NORMA", it is registered in Georgia as a trade mark N° M 18263. Therapeutic efficacy of the drug was investigated in several hundreds of patients with prostatitis.
- Example 1 Patient - male, of age 32, clinical diagnosis: chronic prostatitis of 4 years duration.
- the patient was prescribed 20 suppositories PROSTATA-NORMA, 2 times a day for 10 days.
- PRO ST AT A-NORM A is highly effective drug with prominent anti-inflammatory, antibacterial, antiviral and immune modulating activities. It also has high permeability in the prostate gland tissues.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention refers to medicine, in particular to urology and concerns rectal suppositories that are used for the treatment of prostatitis. The technical result of this invention is widening of assortment of medicinal means for treatment of prostatitis and the reduction of treatment duration. The technical result is achieved in that suppositories contain dipotassium glycyrrhizinate, chymotrypsin in crystalline form, tea tree oil (pharmaceutical form) and diphyllic base.
Description
PROSTATA-NORM RECTAL SUPPOSITORIES FOR THE TREATMENT OF PROSTATITIS
The invention refers to medicine, in particular to urology and concerns rectal suppositories that are used for the treatment of prostatitis.
Currently, several medications are known, in the form of rectal suppositories that are used for the treatment of prostatitis, namely, "Vitaprost" and "Prostatilen" that are approved for clinical use in Russia by the Register of Medicinal Means of Russia (Register of Medicinal Means of Russia "LSP" Moscow, LSR, 2008, p. 293, 815). As an active ingredient these suppositories contain dry extract, obtained from prostate glands of sexually mature animals, that is free of androgen and estrogen hormones and proteins. These suppositories are not characterized with high therapeutic efficacy, possibly because they contain only one active component. There is also another medication, manufactured in Georgia, called "Suppositories for the treatment of prostatitis" (Georgian patent N° 4646, published in the Official Bulletin N°5 on 10.11.2008). This medication contains alcoholic extracts of Calendula and Achillea grisea virens, alcoholic solution of Propolis and Cocoa oil. The treatment by these suppositories is a lengthy process. The technical result of the present invention is widening of assortment of medicaments for treatment of prostatitis and reduction of treatment period. The technical result is achieved in that the medication contains dipotassium glycyrrhizinate , being the derivative of glycyrrhizinic acid, (M.D. Mashkovskyi, "Medicinal Remedies", Moscow, "Medicine", year 2008, Tl-2, pg. 359), chymotrypsin in crystalline form, (proteolytic enzyme) (M.D. Mashkovskyi, "Medicinal Remedies", Moscow, "Medicine", year 2008, Tl-2, pg. 651), tea tree oil (pharmaceutical form) and diphyllic base, thus as a diphyllic base is used Witepsol H-15.
The ratio of active ingredients in grams per one suppositoiy up to 2 g is as follows: Dipotassium glycyrrhizinate 0.025 - 0.1
Chymotrypsin, chrystalline form 0.01- 0.02 Tea tree oil (Melaleucae aetheroleum) 0.015 - 0.05 Witepsol H- 15 up to 2
The unity of medicinal properties of said components makes it possible to create rectal suppositories of high therapeutic efficacy. It is characterized with a wide spectrum of biologic
activities including anti-inflammatory, antibacterial, antiviral, immune modulating effects and is composed of organic, mostly natural substances, without known toxicity.
This medicinal means has high permeability in prostate gland tissues in very short period of time. The process of preparing of suppositories comprises the following steps: first the three components - dipotassium glycyrrhizinate, chymotrypsin in crystalline form and tea tree oil are mixed together. Then the diphyllic base Witepsol H- 15 is added to the resulted mixture and stirred until substance becomes homogenous. As a final step the homogenous mass is poured into the preformed patterns to obtain suppositories. Specific examples of preparing suppositories:
Example 1
Composition in grams per one suppository up to 2 g.:
Dipotassium glycyrrhizinate 0.1
Chymotrypsin in chrystaline form 0.02 Tea tree oil 0.05
Witepsol H- 15 up to 2
Example 2
Composition in grams per one suppository up to 2 g.: Dipotassium glycyrrhizinate 0.05
Chymotrypsin in crystalline form 0.015 Tea tree oil 0.025
Witepsol H- 15 up to 2
Example 3
Composition in grams per one suppository up to 2 g.:
Dipotassium glycyrrhizinate 0.025
Chymotrypsin in crystalline form 0.01
Tea tree oil 0.015 Witepsol H- 15 up to 2
Suppository has a yellowish color and has a smell characteristic of a tea tree oil, and it weighs about 1.5 -2 g. Suppositories can be kept for 2 years; they retain their biologic activity for this long if kept in cool place. The trade name of the suppository is "PROSTATA-NORMA", it is registered in Georgia as a trade mark N° M 18263. Therapeutic efficacy of the drug was investigated in several hundreds of patients with prostatitis.
The obtained data analysis showed substantial improvement in 90% of research population and the obvious improvement in 10% of the study population.
In the course of the treatment there was significant reduction and in some cases the total disappearance of pain, disorders of urination, improvement of lab test results (urinalysis and analysis of prostate gland secretions), in many cases improvement of sexual functions were observed. The above stated results obviate the high therapeutic efficacy of this particular drug.
The real cases from clinical practice of treatment with PROSTAT A-NORM suppositories:
Example 1. Patient - male, of age 32, clinical diagnosis: chronic prostatitis of 4 years duration.
Chief complaints: pain in pubic and inguinal areas, pain is getting worse after sexual intercourse. Sexual dysfunction, in particular premature ejaculation and diminished arousal.
Frequent urination, pain at the end of urination, easy fatigability, anxiety and sleep disorders.
On physical examination: digital rectal examination of prostate gland resulted in enlarged, swollen and painful gland. Margins of the gland are irregular.
Microscopic analysis of prostate gland secretions: visual field is covered with leukocytes, there is marked reduction of lecithin granules and the amount of epithelial cells is increased.
Bacteriologic analysis of the prostate gland secretions: revealed abundant pathogenic E.coli in specimen.
The patient was prescribed 20 suppositories PROSTATA-NORMA, 2 times a day for 10 days.
In 5-7 days of treatment there was significant clinical improvement, pain and urination problems diminished, on the 10th day of treatment microscopic analysis of prostate gland secretions showed the normal range of leukocytes in the visual field (6-8 un the visual field). At the completion of the treatment course sexual function was significantly improved, duration of sexual intercourse increased to 5-8 minutes. One year has passed since the treatment completion and the patient feels healthy. Example 2. Patient - male, of age 41 , clinical diagnosis: chronic prostatitis of 7 years duration.
Chief complaints: pain in inguinal area, pain is referred to the right testis and sacrum. Frequent urination, 8 times a day in the daytime and 12 times a day in the nighttime, there is sticky,
mucosal discharge from the urethra after defecation and during straining. Diminished arousal and decreased duration of sexual intercourse, that resulted in sexual disharmony between spouses and the frequency of sex decreased to one time in 2 weeks.
Patient tried many treatment options including antibiotic therapy, antibacterial drugs and prostate gland massage.
On physical examination: digital rectal examination of prostate gland resulted in enlarged, swollen and painful gland of non-homogenous consistency, with dense and softened areas. Microscopic analysis of prostate gland secretions: there is significant leukocytosis that is arranged in clusters prominent reduction of lecithin granules. Bacteriologic analysis of the prostate gland secretion: revealed abundant S. aureus in specimen. The combined multimodal approach to the treatment included suppositories PROSTATA- NORMA, 2 times a day for 10 days, specific physio-therapeutic procedures and antibacterial drugs. The patient's condition improved significantly, pain and prostatorrhea has disappeared, urination process became normal and on follow-up bacterial analysis S. aureus was not identified. On microscopy leukocytes are in normal range (5-7 in visual field), arousal quality is improved and duration is increased up to 10 min. To consolidate the positive results the second treatment course was administered. After one year the patient feels healthy and his sexual life is normal. Example 3. Patient - male, of age 28, clinical diagnosis: chronic prostatitis of 5 years duration. Chief complaints: pain in the perineal area, that is referred to the sacrum, frequent urination, sense of incomplete emptying of the bladder, diminished arousal, premature ejaculation, pain during orgasm, reduced libido. Because of the sexual problems patient developed "neurosis of anticipated failure", he attempted treatment several times but no desirable results were achieved. On physical examination: digital rectal examination of prostate gland resulted in enlarged, swollen and painful gland. Inter-lobar septum is evened out; there is a palpable density in the left lobe, of a size of a grain. Gland is of non-homogenous consistency.
Microscopic analysis of prostate gland secretions: visual field is completely covered with leukocytes. Bacteriologic analysis of the prostate gland secretions: revealed Proteus mirabillis vulgaris in specimen that was highly sensitive to most of antibiotics.
As a result of treatment, mainly including PRO ST AT A-NORM A suppositories and antibiotics and laser therapy patient improved significantly. Pain and urination problems were gone, sexual
function and the quality of sexual intercourse normalized, that was of particular importance to the patient. Results of the follow-up microscopic and bacteriologic analysis revealed leukocytes in normal range and no pathogenic bacteria. After one year patient is healthy and there were no recurrences of the symptoms during this period.
According to these case reports we can conclude that PRO ST AT A-NORM A is highly effective drug with prominent anti-inflammatory, antibacterial, antiviral and immune modulating activities. It also has high permeability in the prostate gland tissues.
Claims
1. Suppositories for the treatment of prostatitis comprising an active ingredient and the base, characterized in that as an active ingredient it contains dipotassium glycyrrhizinate, chymotrypsin in crystalline form, tea tree oil and diphyllic base.
2. Suppository according to Claim 1 characterized in that as a diphyllic base it contains Witepsol H-15.
3. Suppository for treatment of prostatitis according to claims 1 , 2 characterized in that it contains the components in the following ratio per one suppository of the weight 2g: Dipotassium glycyrrhizinate 0.025 - 0.1
Chymotrypsin in crystalline form 0.01- 0.02
Tea tree oil 0.015 - 0.05
Witepsol H-15 up to 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GEAP200911241A GEP20115319B (en) | 2009-05-01 | 2009-05-01 | Rectal suppositories for treatment of prostate “prostate-norm” |
| GEAP2009011241 | 2009-05-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2010125408A2 true WO2010125408A2 (en) | 2010-11-04 |
| WO2010125408A3 WO2010125408A3 (en) | 2011-03-03 |
Family
ID=43478016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GE2010/000002 WO2010125408A2 (en) | 2009-05-01 | 2010-04-23 | Prostata-norm rectal suppositories for the treatment of prostatitis |
Country Status (2)
| Country | Link |
|---|---|
| GE (1) | GEP20115319B (en) |
| WO (1) | WO2010125408A2 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0597680A (en) * | 1991-10-04 | 1993-04-20 | Sanwa Kagaku Kenkyusho Co Ltd | Glycyrrhizin suppository |
| CN1134293A (en) * | 1995-04-28 | 1996-10-30 | 丁志敏 | Method for producing Chinese and western medicine synthetic injection for treating prostatitis and hyperplasia |
| CN1326780A (en) * | 2001-06-02 | 2001-12-19 | 辛耀禄 | Medicinal capsule for cuirng male sterility and its preparing process |
| CN1520842A (en) * | 2003-01-29 | 2004-08-18 | 谢殿左 | Liposoluble suppository for treating prostatitis |
| CN1562218A (en) * | 2004-04-13 | 2005-01-12 | 云大科技股份有限公司 | Medication combination of compound tea tree oil for preventing or curing inflammation of human genital tract |
| CN1317001C (en) * | 2005-07-28 | 2007-05-23 | 谢作印 | Compound essential oil for treating prostatitis |
-
2009
- 2009-05-01 GE GEAP200911241A patent/GEP20115319B/en unknown
-
2010
- 2010-04-23 WO PCT/GE2010/000002 patent/WO2010125408A2/en active Application Filing
Non-Patent Citations (3)
| Title |
|---|
| M.D. MASHKOVSKYI, MEDICINAL REMEDIES, vol. TI-2, 2008, pages 651 |
| M.D. MASHKOVSKYI, MEDICINAL REMEDIES, vol. TL-2, 2008, pages 359 |
| REGISTER OF MEDICINAL MEANS OF RUSSIA, 2008, pages 293815 |
Also Published As
| Publication number | Publication date |
|---|---|
| GEP20115319B (en) | 2011-10-25 |
| WO2010125408A3 (en) | 2011-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hsu et al. | The effects of isoliquiritigenin on endometriosis in vivo and in vitro study | |
| Abdisa | Mechanism of retained placenta and its treatment by plant medicine in ruminant animals in Oromia, Ethiopia | |
| Takzare et al. | The effect of Achillea millefolium extract on spermatogenesis of male Wistar rats | |
| CN102973829B (en) | Feed for treating diarrhea of dairy cow | |
| CN104721418B (en) | It is a kind of to be used to treat pharmaceutical composition of gynaecological imflammation and preparation method thereof and purposes | |
| CN102475749B (en) | Traditional Chinese medicine transdermal agent for treating dairy cow recessive mastitis and preparation method of transdermal agent | |
| CN103948661B (en) | Pharmaceutical composition and its application for treating gynecological disease, prostatic disorders or anorectal disease | |
| WO2010125408A2 (en) | Prostata-norm rectal suppositories for the treatment of prostatitis | |
| CN110623993A (en) | Compound nutritional tablet of traditional Chinese medicine composition for treating gynecological inflammation and preparation method thereof | |
| CN1911260A (en) | Application of phenolic acids active components from dandelion for inhibiting gynecologic pelvic inflammatory disease | |
| CN107837377A (en) | A kind of warming uterus for dispelling cold patch | |
| KR20110089036A (en) | Functional food composition to improve infertility | |
| CN102949712A (en) | Chinese and western composite medicine for treating neoplastic diseases | |
| CN102697855B (en) | Medicinal composition for treating skin diseases | |
| Johri et al. | Clinical uses of aloe vera in veterinary medicine | |
| CN100408085C (en) | Snow lotus preparation for treating prostate disease | |
| CN104398949A (en) | Traditional Chinese medicine oral liquid for treating prostatitis | |
| US12350335B2 (en) | Homeopathic topical composition | |
| Dahiya et al. | Traditional medicine for cervico-vaginal prolapse management in a buffalo | |
| RU2241471C1 (en) | Suppository for treatment of chronic prostatitis | |
| CN118662561A (en) | Vagina compaction repair composition, vagina compaction repair care solution and preparation method thereof | |
| RU2102061C1 (en) | Method to treat chronic uterine adnexa inflammations | |
| Prabhune et al. | Clinical Efficacy of Modified Dashmoolarishta in Cervicitis | |
| Suresh et al. | Therapeutic effect of Aloe vera on Croton oil induced hemorrhoids. | |
| Jain et al. | Episiotomy Wound Healing and Pain Management in Ayurveda: A Case Study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10719773 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 10719773 Country of ref document: EP Kind code of ref document: A2 |